Regulation of poxvirus vectored vaccines

Vaccine

Volumn 31, Issue 39, 2013, Pages 4259-4260

  Robertson, James S ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Poxvirus vectors; Regulatory Guidelines; Regulatory issues

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; JAPANESE ENCEPHALITIS VACCINE; LIVE VACCINE; POXVIRUS VECTOR; SMALLPOX VACCINE; UNCLASSIFIED DRUG; VACCINE; VIRUS VECTOR;

ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); GENETIC STABILITY; HUMAN; IMMUNOGENICITY; INFECTION; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; QUALITY CONTROL; TROPISM; VIRUS VIRULENCE; YELLOW FEVER FLAVIVIRUS;

POXVIRUS VECTORS; REGULATORY GUIDELINES; REGULATORY ISSUES;

GENETIC VECTORS; GOVERNMENT REGULATION; GUIDELINES AS TOPIC; HUMANS; LICENSURE; POXVIRIDAE; VACCINES, ATTENUATED; VACCINES, DNA; VIRAL VACCINES; WORLD HEALTH ORGANIZATION;

EID: 84882882677     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.05.092     Document Type: Article

References (9)

1. WHO informal consultation on characterization and quality aspect of vaccines based on live viral vectors. Meeting report. Accessed 14 February 2013. http://www.who.int/vaccine_research/documents/viral%20vectors%20report%20full.pdf.
2. Koff W.C., Parks C.L., Berkhout B., Ackland J., Noble S., Gust I.D. Replicating viral vectors as HIV vaccines. Summary Report from IAVI Sponsored Satellite Symposium, International AIDS Society Conference, July 22, 2007. Biologicals 2008, 36:277-286.
3. Excler J.L., Parks C.L., Ackland J., Rees H., Gust I.D., Koff W.C. Replicating viral vectors as HIV vaccines: Summary report from the IAVI-sponsored satellite symposium at the AIDS vaccine 2009 conference. Biologicals 2010, 38:511-521.
4. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Guideline on quality, non-clinical and clinical aspects of live recombinant viral vectored vaccines. EMA/CHMP/VWP/141697/2009. Accessed 14 February 2013. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/08/WC500095721.pdf.
5. European Medicines Agency, Committee for Medicinal Products for Veterinary Use (CVMP). Guideline on live recombinant vector vaccines for veterinary use. EMEA/CVMP/004/04-final. Accessed 14 February 2013. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/10/WC500004590.pdf.
6. Directive 2001/18/EC on the deliberate release into the environment of GMOs. Accessed 14 February 2013. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do%3Furi=OJ%3AL%3A2001%3A106%3A0001%3A0038%3AEN%3APDF.
7. Environmental risk assessments for medicinal products consisting of, or containing, genetically modified organisms (GMOs) (EMEA/CHMP/BWP/473191/2006 - Corr). Accessed 14 February 2013. http://www.ema.europa.eu/pdfs/human/bwp/47319106en.pdf.
8. World Health Organization. Recommendations for the production and quality control of smallpox vaccine, revised 2003. WHO Technical Report Series 2004; 926: 27-64. Accessed 14 February 2013. http://www.who.int/biologicals/publications/trs/areas/vaccines/smallpox/Annex%201%20(27-64)TRS926Smallpox2003.pdf.
9. European Medicines Agency, Committee for Proprietary Medicinal Products (CPMP). Note for guidance on the development of vaccinia virus based vaccines against smallpox. CPMP/1100/02. Accessed 14 February 2013. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003900.pdf.